Browsing Tag
Fortress Biotech
2 posts
Crystalys Therapeutics doses first patients in Fortress Biotech’s global Phase 3 gout trial of Dotinurad, targeting safer uric acid control
Find out how Fortress Biotech’s Dotinurad is advancing in global Phase 3 trials and why it could redefine gout therapy worldwide.
October 21, 2025
Zydus Group’s Sentynl Therapeutics gains full control of Menkes Disease candidate CUTX-101
Sentynl Therapeutics, Inc., a U.S.-based biopharmaceutical company under Zydus Lifesciences, Ltd., has finalized an agreement with Cyprium Therapeutics,…
December 6, 2023